Lopinavir inhibits insulin signaling by promoting protein tyrosine phosphatase 1B expression

Experimental and Therapeutic Medicine

Volumn 8, Issue 3, 2014, Pages 851-855

  Kitazawa, Takatoshi ^a   Yoshino, Yusuke ^a   Suzuki, Satoshi ^b   Koga, Ichiro ^a   Ota, Yasuo ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Darunavir; Insulin; Lopinavir; Protein tyrosine phosphatase 1B

Indexed keywords

DARUNAVIR; GLUCOSE TRANSPORTER 4; INSULIN RECEPTOR SUBSTRATE 1; LOPINAVIR; PROTEIN TYROSINE PHOSPHATASE 1B; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; IMMUNODETECTION; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; INSULIN SIGNALING; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 84904392188     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1826     Document Type: Article

References (24)

1. May MT, Sterne JA, Costagliola D, et al; Antiretroviral Therapy (ART) Cohort Collaboration: HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 368: 451-458, 2006.
2. Honda M and Oka S: Current therapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Int J Hematol 84: 18-22, 2006.
3. Murata H, Hruz PW and Mueckler M: The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 275: 20251-20254, 2000.
4. Nolte LA, Yarasheski KE, Kawanaka K, Fisher J, Le N and Holloszy JO: The HIV protease inhibitor indinavir decreases insulin-and contraction-stimulated glucose transport in skeletal muscle. Diabetes 50: 1397-1401, 2001.
5. Djedaini M, Peraldi P, Drici MD, et al: Lopinavir co-induces insulin resistance and ER stress in human adipocytes. Biochem Biophys Res Commun 386: 96-100, 2009.
6. Wellen KE and Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 115: 1111-1119, 2005.
7. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL and Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808, 2003.
8. Dalpke A, Heeg K, Bartz H and Baetz A: Regulation of innate immunity by suppressor of cytokine signaling (SOCS) proteins. Immunobiology 213: 225-235, 2008.
9. Ueki K, Kondo T and Kahn CR: Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24: 5434-5446, 2004.
10. Asante-Appiah E and Kennedy BP: Protein tyrosine phosphatases: the quest for negative regulators of insulin action. Am J Physiol Endocrinol Metab 284: E663-E670, 2003.
11. Tordjman KM, Leingang KA, James DE and Mueckler MM: Differential regulation of two distinct glucose transporter species expressed in 3T3-L1 adipocytes: effect of chronic insulin and tolbutamide treatment. Proc Natl Acad Sci USA 86: 7761-7765, 1989.
12. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685, 1970.
13. Eron JJ, Feinberg J, Kessler HA, et al: Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis 189: 265-272, 2004.
14. Curran A, Gutirerrez M, Deig E et al: Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients. J Antimicrob Chemother 65: 2195-2203, 2010.
15. Patick AK and Potts KE: Protease inhibitors as antiviral agents. Clin Microbiol Rev 11: 614-627, 1998.
16. Bogachus LD and Turcotte LP: HIV protease inhibitors induce metabolic dysfunction in part via increased JNK1/2 pro-inflammatory signaling in L6 cells. Antiviral Res 92: 415-423, 2011.
17. Sun XJ and Liu F: Phosphorylation of IRS proteins Yin-Yang regulation of insulin signaling. Vitam Horm 80: 351-387, 2009.
18. Ismail WI, King JA, Anwar K and Pillay TS: Indinavir and nelfinavir inhibit proximal insulin receptor signaling and salicylate abrogates inhibition: potential role of the NFkappa B pathway. J Cell Biochem 114, 1729-1737, 2013.
19. Goldstein BJ, Bittner-Kowalczyk A, White MF and Harbeck M: Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. J Biol Chem 275: 4283-4289, 2000.
20. Ben-Romano R, Rudich A, Tirosh A et al: Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-zeta. Diabetologia 47: 1107-1117, 2004.
21. Schütt M, Zhou J, Meier M and Klein HH: Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells. J Endocrinol 183: 445-454, 2004.
22. Noor MA, Flint OP, Maa JF and Parker RA: Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 20: 1813-1821, 2006.
23. Tomaka F, Lefebvre E, Sekar V, et al: Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. HIV Med 10: 318-327, 2009.
24. Björnholm M, Kawano Y, Lehtihet M and Zierath JR: Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 46: 524-527, 1997.